CohBar anticipates data from its drug to treat obesity in the "coming months"

Philippe P. Calais, CEO of CohBar (NASDAQ: CWBR), has spoken with proactive investors at the BIO CEO & Investor Conference in New York.

CohBar is a clinical-stage biotechnology company specializing in the research and development of Mitochondrial Therapy (MBT), a new clbad of drugs for the treatment of age-related diseases.